Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update.
Ontology highlight
ABSTRACT: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) worldwide. Its pathogenesis encompasses functional alterations involving elevated intraglomerular and systemic pressure, increased activity of the renin-angiotensin system (RAS) and oxidative stress, and the eventual development of renal fibrosis. The management of DN involves the optimization of blood pressure (BP) and blood glucose targets. However, treatment of these risk factors slows down but does not stop the progression of DN. Innovative pharmacologic therapies for dyslipidemia and type 2 diabetes mellitus (T2DM) could play a key role in bridging this gap and attenuating the residual risk of DN beyond traditional risk factor management. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-gluco
SUBMITTER: Giglio RV
PROVIDER: S-EPMC9953496 | biostudies-literature | 2023 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA